Drugs / iluzanebart
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05677659 | Dec 2022 → Feb 2025 | leukoencephalopathy, diffuse hereditary, with spheroids 1 | Vigil Neuroscience, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iluzanebart | “This is a multicenter, open-label study to assess the safety and tolerability of iluzanebart (also referred to as VGL101) in subjects with documentation of a gene mutation in...” NCT05677659 ↗ |
| Known as | VGL101 | “This is a multicenter, open-label study to assess the safety and tolerability of iluzanebart (also referred to as VGL101) in subjects with documentation of a gene mutation in...” NCT05677659 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5315043 ↗ |
| Route | Intravenous | “Solution administered via Intravenous Infusion (IV)” NCT05677659 ↗ |